A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
NCT04067999 · Completed
Last updated 2026-05-28This study is testing how the medication semaglutide affects people with type 2 diabetes in Spain as part of their regular medical care.
What this study is testing ClinicalTrials.gov NCT04067999 ↗
Description as written by the study sponsor.
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.
Treatments tested
- Semaglutide Drug
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
| Main thing measured | Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04067999 ↗